Skip to content
DraconiticResearch
Search Sources API
190,335 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

523 Lymphaticsparing neoadjuvant SABR and pembrolizumab (neo-ImmunoSABR) in HPVnegative HNSCC: results from a phase II multi-center trial with immune correlates

  • Hong Xiao1
  • Ashish Patel2
  • Marka Crittenden3
  • Kristina Young4
  • Ezra Cohen5
  • Robert Saddawi-Konefka6
  • Andrew Sharabi7
  • J Silvio Gutkind8
  • Alexandra Q Bartlett9
  • Rom S Leidner9
  • Brian D Piening9
  • Steven Seung10
8 more authors
  • Matthew H Taylor9
  • Thomas M Duhen11
  • Bernard A Fox11
  • Alexa K Dowdell11
  • Douglas A Hanes12
  • Liza Blumenfeld13
  • Joseph A Califano14
  • Bryan R Bell12
14 affiliations
  1. 1National Clinical Research Center for Geriatric Diseases (Xiangya Hospital), Changsha, China
  2. 2The Royal Wolverhampton NHS Trust, Wolverhampton, UK
  3. 3Department of Radiation Oncology, Providence Portland Medical Center, Portland, Oregon, USA
  4. 44Earle A. Chiles Research Institute, Portland, OR, USA
  5. 5Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA
  6. 6Moores Cancer Center, La Jolla, CA, USA
  7. 710Moores Cancer Center, La Jolla, CA, USA
  8. 82UC San Diego Health, San Diego, CA, USA
  9. 9Earle A. Chiles Research Institute, Portland, OR, USA
  10. 10The Oregon Clinic, Portland, OR, USA
  11. 11Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
  12. 12Providence Cancer Institute, Portland, OR, USA
  13. 13Moores Cancer Center, San Diego, CA, USA
  14. 14Department of Otolaryngology-Head and Neck Surgery, University of California San Diego School of Medicine, San Diego, CA, USA
Open at sourceDOICite

Related

  1. Case Report: Pembrolizumab-associated airway-predominant relapsing polychondritis with longitudinal CD8+ T-cell activation and bronchial stenting
    Can Xia, Jie Chen, Xia Fang +4
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossref
  2. A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
    Michael S. Oh, Aaron E. Lisberg, Camelia Dumitras +28
    Nature CommunicationsPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCPMC
  3. FLOT versus SOX as immunochemotherapy backbones for neoadjuvant or conversion therapy in gastric cancer: efficacy, toxicity, and postoperative safety in a real-world cohort
    Penghui Liu, Na Li, Jiwu Guo +3
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC
  4. Commentary: Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity
    Bingqiang Li, Chenyu Song, Hang Li +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  5. Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures
    Xue Peng Rao, Xin Chang Zou, Xiang Liu +5
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{xiao2026lymphaticsparing,
  title = {{523 Lymphaticsparing neoadjuvant SABR and pembrolizumab (neo-ImmunoSABR) in HPVnegative HNSCC: results from a phase II multi-center trial with immune correlates}},
  author = {Hong Xiao and Ashish Patel and Marka Crittenden and Kristina Young and Ezra Cohen and Robert Saddawi-Konefka and Andrew Sharabi and J Silvio Gutkind and Alexandra Q Bartlett and Rom S Leidner and Brian D Piening and Steven Seung and Matthew H Taylor and Thomas M Duhen and Bernard A Fox and Alexa K Dowdell and Douglas A Hanes and Liza Blumenfeld and Joseph A Califano and Bryan R Bell},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0523},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0523},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 523 Lymphaticsparing neoadjuvant SABR and pembrolizumab (neo-ImmunoSABR) in HPVnegative HNSCC: results from a phase II multi-center trial with immune correlates
AU  - Hong Xiao
AU  - Ashish Patel
AU  - Marka Crittenden
AU  - Kristina Young
AU  - Ezra Cohen
AU  - Robert Saddawi-Konefka
AU  - Andrew Sharabi
AU  - J Silvio Gutkind
AU  - Alexandra Q Bartlett
AU  - Rom S Leidner
AU  - Brian D Piening
AU  - Steven Seung
AU  - Matthew H Taylor
AU  - Thomas M Duhen
AU  - Bernard A Fox
AU  - Alexa K Dowdell
AU  - Douglas A Hanes
AU  - Liza Blumenfeld
AU  - Joseph A Califano
AU  - Bryan R Bell
PY  - 2026
DA  - 2026/11/04
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0523
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0523
SN  - 2051-1426
ER  -